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A fluorometric analytical method was developed for quantification of protoporphyrin IX (PpIX) in skin 
samples and receptor phase solution after in vitro cutaneous penetration/permeation studies. Analytical 
conditions used were: excitation and emission wavelengths: 400 nm and 632 nm; bandwidth: 0.5 nm; 
excitation and emission slits: 10/10. PpIX was recovered from two different layers of skin, the stratum 
corneum (SC) and the epidermis plus dermis ([E+D]), by vortex homogenization, probe and bath 
sonication, using DMSO as an extraction solvent. The detection and quantification limits were 0.002 and 
0.005 µg/mL, respectively. The assay was linear from 0.005 – 0.5 µg/mL. The within-day and between-
day assay precision and accuracy in DMSO and receptor phase solution were each studied at the two 
concentration levels 0.04 and 0.2 µg/mL, and 0.01 and 0.08 µg/mL, respectively. The coefficients of 
variation and deviation from the theoretical values were lower than 5%. The skin recovery of PpIX from 
SC and [E+D] layers using two different concentrations (0.5 and 1.0 µg/mL) were all above 90.0%. 
The method described has potential application to in vitro penetration/permeation studies of PpIX using 
porcine skin as a biological membrane model.
Uniterms: Fluorometric quantification. Protoporphyrin IX/determination. Photodynamic therapy. Porcine 
skin. Cutaneous penetration/in vitro study. Cutaneous permeation/in vitro study.
Um método analítico por espectrofluorimetria foi desenvolvido para quantificar a protoporfirina IX (Pp 
IX) em amostras de pele e fase receptora após a realização de testes in vitro de penetração/permeação 
cutâneas. As condições analíticas utilizadas foram: comprimentos de onda de excitação e emissão: 
400 nm e 632 nm; largura de banda: 0,5 nm; fendas de excitação e emissão: 10/10. A PpIX foi extraída de 
amostras de estrato córneo (EC) e da epiderme sem estrato córneo + derme ([E+D]) através da agitação 
em vórtex e sonicação por haste e banho, utilizando-se o DMSO como solvente extrator. O limite de 
detecção e quantificação foram, respectivamente, de 0,002 e 0,005 µg/mL. O método mostrou-se linear 
da faixa de 0,005 – 0,5 µg/mL. A precisão e exatidão intra e inter-ensaio em DMSO e na fase receptora 
foram validadas utilizando-se duas concentrações distintas, respectivamente, de 0,004 e 0,2 µg/mL, e 
0,01 e 0,08 µg/mL. Os valores de coeficiente de variação e o desvio do valor teórico foram inferiores 
a 5%. A recuperação da PpIX das camadas da pele (EC e [E+D]) utilizando-se duas concentrações 
distintas (0,5 e 1,0 µg/mL) foram todas acima de 90,0%. O método descrito pode ser utilizado para 
determinação da PpIX após estudos de penetração/permeação cutânea in vitro utilizando pele de porco 
como modelo de membrana.
Unitermos: Espectrofluorimetria/análise quantitativa. Quantificação fluorimétrica. Protoporfirina IX/
determinação. Terapia fotodinâmica. Pele porcina. Penetração cutânea/estudo in vitro. Permeação 
cutânea/estudo in vitro.
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INTRODUCTION
Fluorescence spectroscopy has gained increasing 
importance in recent years, especially in molecular and 
cellular biology, and in many associated areas of bio-
chemical analysis, because it offers many advantages such 
as extreme sensitivity, a high degree of selectivity, and 
exceptional flexibility in measuring a range of solid and 
liquid sample formats (Miller, 2006).
Fluorescence detection of a molecule capable of 
emitting fluorescence efficiently, called a photosensi-
tizer (PS), is an analytical and sensitive method used to 
quantify the amount of PS in cells or tissues, and allows 
in vivo fluorescence imaging in living animals or patients 
to measure the pharmacokinetics and distribution of the 
PS (Castano, Demidova, Hamblin, 2004). Moreover, PSs 
are currently been used to treat different types of cancer, 
including non-melanoma skin cancers in a therapy called 
photodynamic therapy, that produces highly reactive lethal 
substances for tumorous cells through the combination 
of light, PS and oxygen (Brown, Brown, Walker, 2004; 
Zeitouni, Oseroff, Shieff, 2003).
The study of the use of protoporphyrin IX (PpIX), 
an endogenous porphyrin, as a PS is promising because it 
has fast degradation in normal tissue compared to abnor-
mal tissue, which leads to a short period of sensitization 
thereby reducing the collateral effects of the photodynamic 
therapy (Kennedy, Pottier, Pross, 1990). In addition, its 
topical administration in the treatment of non-melanoma 
skin cancer in comparison to systemic application can be 
more efficient, since higher local concentrations in the 
cancerous tissue can be obtained (Rick et al., 1997).
Because the skin penetration and permeation of 
most PSs remains unknown, it is crucial to quantify 
accurately and precisely the skin uptake and transder-
mal delivery of these compounds in the development of 
topical formulations. The main method to study the drug 
release performance into/through the skin is the in vitro 
test performed in a Franz Diffusion Cell using pig’s ear 
skin as a biological model for skin (Schmook, Meingas-
sner, Billich, 2001).
The physicochemical characteristics of the PpIX 
allows the development of an analytical method for its 
quantification based on fluorescence spectroscopy, since 
this PS is able to emit fluorescence after excitation by 
a beam of light with an adequate wavelength (Castano, 
Deminova, Hamblin, 2004; De Rosa et al., 2000).
The aim of the present study was to contribute to the 
area of topical drugs development, through the develop-
ment of an accurate and precise method to quantify PpIX 
in skin samples from cutaneous penetration/permeation in 
vitro tests. To this end, a fluorometric analytical method 
was validated.
MATERIAL AND METHODS
Standard solutions and chemicals
A standard solution of PpIX (50 µg/mL) in dime-
thylsulfoxide (DMSO) was prepared and stored in the 
dark at –5 ºC for 15 days. Working solutions (0.005 to 
2.0 µg/mL) were prepared by appropriate dilutions with 
DMSO and phosphate buffer (100 mM, pH 7.2) - contai-
ning cetylpyridinium chloride (CPC) at 30 mM – and were 
freshly used. DMSO of analytical grade was purchased 
from Merck (Germany).
Equipment and spectrofluorometric conditions
Fluorometric quantification and validation were 
performed using a Hitachi – F-4500 (Tokyo, Japan) spec-
trofluorometer (λ excitation: 400 nm; λ emission: 632 nm; 
bandwidth: 0.5 nm; excitation and emission slit: 10/10). 
Skin preparations
The penetration of PpIX in the skin was assessed 
using an in vitro model of porcine ear skin, as previously 
described (Lopez et al., 2001). Briefly, the skin from 
the outer surface of a freshly excised porcine ear was 
carefully dissected (making sure that the subcutaneous 
fat was maximally removed), stored at -20 ºC, and used 
within a month.
PpIX recovery from porcine skin samples
The absolute recovery of PpIX from skin tissue was 
determined for two concentrations (0.5 and 1.0 µg/mL). 
This was performed by spiking samples of adhesive tape 
(14 pieces) containing stratum corneum (SC), subjected to 
tape stripping, and the remaining skin sections (0.78 cm2), 
referring to epidermis (E) plus dermis (D) tissue, with a 
PpIX solution in DMSO (10.0 µg/mL). The spiked skin 
samples (n = 5), SC and [E+D], were allowed to rest for 
60 minutes before PpIX extraction. The PpIX extraction 
from the adhesive tapes containing the SC and [E+D] 
was done as follows: each skin sample was immersed in 
4 mL of DMSO; the system was vortex stirred for 2 min; 
bath sonicated (40 KHz, continuous mode) for 30 minutes 
and the resulting mixture was then filtrated using 0.45 
µm membranes, and PpIX determined in the filtrate by 
spectrofluorometric assay. The [E+D] samples were cut 
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into small pieces before being immersed in DMSO and 
submitted to probe sonication (22.5 kHz) for 30 seconds 
after vortex stirring and before bath sonication.
PpIX solubility and aggregation behavior in 
Phosphate Buffer (100 mM, pH 7.2)
The receptor phase developed for the in vitro 
penetration studies was a phosphate buffer (100 mM, 
pH 7.2) containing the cationic surfactant CPC at 30 mM 
(concentration above surfactant critical micelle concen-
tration- CMC). PpIX solubility and monomerization 
in the receptor phase were checked for possible PpIX 
quantification.
The solubility of PpIX was determined (n = 3) by 
adding an excess amount of PpIX in 5 mL of the receptor 
phase and leaving this overnight under constant stirring. 
Subsequently, the samples were centrifuged at 704.0 g 
for 10 minutes and filtrated using 0.45 µm membranes, 
and PpIX was determined spectrophotometrically in the 
filtrate by using a UV-vis FEMTO 800 XI. To verify the 
aggregation behavior of PpIX in the receptor phase, the 
absorption spectrum from a 2.0 µg/mL PpIX receptor 
phase solution was compared to the spectrum in the same 
PpIX concentration in a monomeric solution (DMSO).
In vitro skin penetration/permeation
The assay developed for PpIX quantification in 
porcine skin was used to determine PpIX skin penetra-
tion after in vitro cutaneous penetration experiments. On 
the day of the experiment, the cleaned porcine ear skin 
was mounted in a Franz diffusion cell (diffusion area 
of 0.78 cm2; Hanson Research, Chatsworth, CA, USA), 
with the SC facing the donor compartment and the dermis 
facing the receptor compartment, which was filled with 
the receptor phase of 100 mM phosphate buffer (pH 7.2) 
containing CPC at 30 mM for PpIX solubilization. 
The system was maintained at 37 ºC and under cons-
tant stirring. Five hundred milligrams of a solution com-
posed of PpIX at 80 µg/mL (w/w) in polyethylene glycol 
(PEG) (n=5) was applied to the surface of the SC (in the 
donor compartment), and the concentration of PpIX in the 
SC and [E+D] was determined at 12 h post-application. At 
the end of the experiment, skin surfaces were thoroughly 
washed with distilled water to remove excess formulation. 
PpIX was extracted from SC and [E+D] using the metho-
dology described above (in the item PpIX recovery from 
porcine skin). The amount of drug detected in SC and in 
[E+D] was indicative of drug penetration into the skin. The 
amount of drug detected in the receptor phase (phosphate 
buffer pH 7.2 + CPC) was indicative of drug permeation 
through the skin.
The samples from the SC, [E+D] and permeation 
(receptor phase) protected from light were stable for 24 
hours at room temperature after the 12 h in vitro penetra-
tion/permeation experiment.
PpIX assay specifications
The validation of a bioanalytical method is the 
process used to establish that analytical performance 
parameters are adequate for their intended use (Causon, 
1997). Based on this, we evaluated several parameters to 
demonstrate that the analytical procedure was suitable for 
analyzing PpIX in skin and receptor phase samples from 
in vitro skin penetration studies.
Linearity responses were verified by using DMSO 
and receptor phase solutions of PpIX in concentrations 
ranging from 0.005 to 1.5 µg/mL. The precision and 
accuracy of the method were tested on a within-day and 
between-day basis. For the determination of the within-
day precision and accuracy, ten (10) PpIX DMSO and 
receptor phase solution replicate aliquots at concentrations 
of 0.04 and 0.2 µg/mL and 0.01 and 0.08 µg/mL, respec-
tively, were analyzed. The between-day precision and 
accuracy were determined by analyzing 5 aliquots of the 
same PpIX solutions on five consecutive days. The range, 
defined as the interval between the high and low levels of 
the analyte studied, was obtained based on the linearity. 
The within-day precision and accuracy of the lower limit 
of quantification (LOQ) were determined by analyzing 7 
aliquots of the same PpIX solutions.
The precision of the assay was calculated as the 
relative standard deviation (coefficient of variation, CV), 
whereas the accuracy was calculated as the relative error of 
the mean, between expected and calculated concentrations, 
according to the following equation:
Accuracy (%) = (calculated mean - theoretical/
theoretical) x 100. 
The requirements are met if CV for each concen-
tration does not exceed 15% (Causon, 1997; ANVISA 
resolution number 899), except for LOQ, for which larger 
values (up to 20%) are allowed (ANVISA resolution num-
ber 899, Shah et al., 1992).
The sensitivity of the method was evaluated by 
determining the lower LOQ and the detection limit. The 
LOQ was set as the lowest PpIX concentration that could 
be determined with adequate precision and accuracy, whe-
reas the lower limit was the lowest PpIX concentration that 
could be detected but not quantified under the stated expe-
rimental conditions (Causon, 1997; Santana et al., 2004). 
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The detection and quantification limits were calculated 
by analyzing diluted solutions of PpIX in concentrations 
ranging from 0.001 – 0.005 µg/mL.
The selectivity of the method was verified by evalu-
ating the interference of skin compounds and of the adhe-
sive tape on the assay of PpIX. Samples of control skin 
(treated with Milli Q water) were submitted to the same 
procedure to extract PpIX, as described in the item PpIX 
recovery from porcine skin. The homogenates of SC and 
[E+D] were assayed spectrofluorometrically.
Calibration curves
Calibration curves to assay PpIX in skin samples 
were constructed by assaying DMSO solutions of the drug 
at concentrations ranging from 0.005 to 0.1 μg/mL.
RESULTS AND DISCUSSION
PpIX is the immediate precursor of haem in the bio-
synthetic pathway for haem. It is an endogenous PS that 
is transiently intracellularly accumulated after an excess 
of exogenous 5-aminolevulinic acid (5-ALA) bypasses 
the negative feedback control mechanism of 5-ALA syn-
thesis (Kennedy; Pottier; Pross, 1990). PpIX is the drug 
assayed in blood, biological matrices and tissues after 
5-ALA administration. The main methods developed for 
its quantification are spectrofluorometry (Pierre et al., 
2006; Steluti et al., 2005) and HPLC with fluorescence 
(Boddé, Roemelé, Star, 2002; De Rosa et al., 2003; Oishi 
et al., 1996) or ultraviolet detection (Mateo et al., 2004).
DMSO was chosen to extract PpIX from the skin 
in the in vitro penetration experiments due to its solvent 
properties and PpIX’s good solubility in this medium. 
According to Scolaro et al. (2002), porphyrins exhibit 
aggregation, a π-π stacking interaction in water while 
spectroscopic studies performed in water as a function of 
pH demonstrated that they are monomer between pH 0-3; 
dimmer in pH above 8 and higher aggregates in the pH 
3-7. At pH 1, PpIX absorption spectra exhibits a strong 
absorption band (B-band) at λ (nm) = 406 (1.7) and four 
weaker absorption bands (Q-bands) at λ (nm) = 516 (9.6); 
554 (17.2); 600 (11.6) and 626 (8.0). Similarly, in DMSO 
where PpIX is a monomer, the B-band is located at λ (nm) 
= 408 (1.7) and Q-bands are at λ (nm) = 506 (16.4); 542 
(13.3); 577 (8.6); 630 (6.2). The emission spectra in water 
at pH 1 exhibits two fluorescence bands at λ (nm) = 604 
and 660, and in DMSO at λ (nm) = 624 and 684. 
In order to avoid strong acidic media that would pro-
mote PpIX monomer form in the receptor phase from the 
in vitro experiments, we chose to use a cationic surfactant 
CPC at 30 mM (concentration above its C.M.C.) to pro-
mote PpIX monomerization in this phase. PpIX solubility 
performed in this phase was 31.66 ± 0.65 μg/mL. PpIX is 
an anionic molecule and spectroscopic studies performed 
in aqueous media containing the cationic surfactant named 
hexadecyltrimethylammonium bromide demonstrated 
good PpIX solubilization due to electrostatic interactions, 
reflecting a strong absorption band (B-band) at λ (nm) = 
409, and four weaker absorption bands (Q-bands) at λ (nm) 
= 505; 540; 578; 632; and strong fluorescence emission 
at λ (nm) = 633 (Sivash; Masinovsk; Lozovaya, 1991).
The absorption spectrum (Figure 1) in DMSO and 
phosphate buffer containing CPC demonstrated a strong 
absorption band (B-band) at λ (nm) = 406 and 408 and 
four weaker absorption bands (Q-bands) at λ (nm) = 506; 
540; 574 and 576 and 630 and 632, respectively. The 
emission spectrum (Figure 2) in the same media demons-
trated strong fluorescence emission at λ (nm) = 632 and 
634, respectively. Similar behavior to PpIX spectra were 
FIGURE 1 - Normalized absorption spectra of PpIX (2.0 μg/mL) 
in the solvents used for the in vitro penetration studies.
FIGURE 2 - Normalized fluorescence spectra of PpIX (2.0 μg/mL) 
in the solvents used for the in vitro penetration studies. 
Specifications: λ excitation (nm) = 400/λmax. emission (nm) = 
632 and 634; excitation/emission Slits: 5.0/5.0 nm.
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TABLE I - Analysis of the precision and accuracy of the fluorometric method for PpIX assay in DMSO
Parameters Protoporphyrin IX
Precision (within-day)
Nominal standard concentration (µg/mL) a0.005 0.04 0.2
N 7 10 10
C.V. (%) 6.9 1.5 0.9
Precision (between-day)
Nominal standard concentration (µg/mL) ------ 0.04 0.2
N ------ 5 5
C.V. (%) ------ 1.1 1.1
Accuracy
Within-day (%) -15.3 2.3 -0.5
Between-day (%) ------ 0.9 -0.6
N: number of determination; C.V., coefficient of variation; a lower limit of quantification.
described in the previously cited studies, confirming PpIX 
monomer form in these solvents.
Fluorescence emission is a sensitive and reliable tool 
for measuring PpIX in ex vivo tissue (Pierre et al., 2006; 
Steluti et al., 2005). The selectivity of the method is related 
to the autofluorescence of the skin and adhesive tape com-
pounds which can fluoresce in the same λ of the PS. The 
main endogenous compounds (fluorophores) in pig skin, 
which determine the fluorescence signal of normal skin, 
are similar to those found in humans and the differences are 
related to the different content of a specific fluorophore in 
the animal cutaneous tissue and different percentage of an 
exact compound type – for example, collagen (Drakaki et 
al., 2007). The maximum λ emission for PpIX determined 
in DMSO was around 630 nm when excited at λ = 400 nm 
(Figure 3). However, the fluorescence of the SC and [E+D] 
of pig skin homogenates and adhesive tape compounds did 
not show any fluorescence intensity around this λ (630 nm) 
enabling PpIX assay in in vitro skin penetration studies. 
According to Drakaki et al. (2007), the pig skin spectrum 
(ex vivo and after defrosting) of its autofluorescence, after 
UV laser excitation at λ = 337.1 nm, exhibits two maxima 
in the region of 390 and 440 nm, which could be addressed 
to collagen (type, I and VI) fluorescence. Slight influence of 
oxy-hemoglobin absorption yields minima in fluorescence 
signals at 420, 545 and 575 nm. 
The fluorometric method described in the present 
study has the advantage of rapid and sensitive quantifica-
tion of PpIX retained in the skin. Fluorescence intensity of 
the PS linearly correlated with concentrations in the range 
0.005-0.5 μg/mL for DMSO and phosphate buffer pH 7.2 
+ CCP. The equation for a typical calibration curve, ob-
tained by least squares linear regression, was y = 19,002x 
FIGURE 3 - Spectra referring to analyses of homogenates of 
SC and [E+D] in comparison to the profile of a 5 μg/mL PpIX 
solution (DMSO) to evaluate the selectivity of the method. 
Specifications: Conditions: excitation λ: 400 nm; emission λmax.: 
632 nm; emission/excitation slits: 5/10 nm.
+ 171.6; r= 0.998 (DMSO) and y = 15,230x + 144.3; r= 
0.998 (phosphate buffer pH 7.2 + CCP).
The within-day precision and accuracy of the assay 
were obtained by sequential analysis of PpIX solutions in 
DMSO at two distinct concentrations (0.04 and 0.2 μg/ mL). 
The within-day assay coefficients of variation (CV) for 
PpIX were lower than 2.0% and all between-day assay 
coefficients of variation were below 1.5% (Table I). The 
within-day and between-day assay accuracies were found 
to be 2.3 and 0.9% for 0.04 μg/mL, -0.5 and -0.6% for 
0.2 μg/mL, respectively. 
The within-day precision and accuracy of the assay 
were also obtained by sequential analysis of PpIX solu-
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tions in phosphate buffer pH 7.2 + CCP at two distinct 
concentrations (0.01 and 0.08 μg/ mL). The within-day 
assay coefficients of variation (CV) for PpIX were lo-
wer than 2.5% and all between-day assay coefficients 
of variation were below 4.0% (Table II). The within-day 
and between-day assay accuracies were found to be 
0.01 and -0.9% for 0.01 μg/mL, -0.13 and -0.002% for 
0.08 μg/mL, respectively.
The detection limit of the assay was 0.002 μg/mL for 
DMSO and phosphate buffer pH 7.2 + CCP. The lowest 
concentration quantified by this method with acceptable 
precision and accuracy was 0.005 μg/ml. This limit is ade-
quate for the assessment of PpIX retained in the skin, since 
the PS is lipophilic, and is expected to be retained within 
the SC and [E+D] rather than to permeate across the skin.
Table III shows the results of PpIX recovery, extrac-
ted from the skin samples (SC and [E+D]). The recovery 
from SC and [E+D] for the two concentrations tested (0.5 
and 1.0 µg/mL) were all above 90.0% of the spiked dose 
(n=5). No studies describing the recovery of PpIX from 
skin samples were found in the literature. Studies focusing 
on the validation of topical drug recovery from porcine 
skin obtained variable results, ranging from an average 
of 82.0% (Ayub, Vianna-Soares, Ferreira, 2007), 97.0% 
(Echevarria et al., 2003) and above 94.0% (Santoyo et al., 
2002). According to Causon (1997), and compared with 
the recovery obtained by the studies described above, the 
method for PpIX extraction from skin layers in this paper 
resulted in a high PpIX recovery, demonstrating its sui-
tability for application in cutaneous penetration studies.
The present fluorometric method developed for 
PpIX quantification in skin samples proved to be suita-
ble for PpIX assay in different skin layers after in vitro 
penetration studies. At 12 h post-application, 0.13±0.01 
μg/cm2 (n=5) of PpIX was detected in the SC, and 
0.016±0.002 μg/cm2 in the [E+D] (Figure 4). PpIX was 
not detected in the receptor samples (phosphate buffer 
pH 7.2 + CCP) of the experiment probably because it is 
a high molecular weight lipophilic drug that does not 
TABLE II - Analysis of the precision and accuracy of the fluorometric method for PpIX assay in phosphate buffer pH 7.2 + CPC
Parameters Protoporphyrin IX
Precision (within-day)
Nominal standard concentration (µg/mL) a0.005 0.01 0.08
N 7 10 10
C.V. (%) 1.8 2.2 1.2
Precision (between-day)
Nominal standard concentration (µg/mL) ------ 0.01 0.08
N ------ 5 5
C.V. (%) ------ 3.5 1.3
Accuracy
Within-day (%) -1.9 0.01 -0.13
Between-day (%) ------ -0.9 -0.002
N: number of determination; C.V., coefficient of variation; a lower limit of quantification
TABLE III - PpIX recovery from SC and [E+D] samples
Sample Skin layers
SC [E+D]
PpIX added (μg/mL) 0.5 1.0 0.5 1.0
PpIX extracted (μg/mL) 0.47 0.90 0.48 0.95
N 5 5 5 5
Recovery (%) 94.0 90.0 96.0 95.0
SC= stratum corneum; [E+D]= epidermis without stratum 
corneum + dermis; N = number of replicates.
FIGURE 4 - PpIX in vitro penetration in the SC and [E+D] 
at 12 hours post-application of a photosensitizer solution in 
polyethylene glycol (80 μg/mL). Results presented are expressed 
as averages ± SEM of five experiments.
Fluorometric quantification of protoporphyrin IX in biological skin samples from in vitro penetration/permeation studies 759
permeate the skin without a proper delivery system or 
the use of penetration enhancers.
CONCLUSION
The development of a fluorometric method for PpIX 
quantification in skin and permeation samples from in vitro 
penetration/permeation studies proved to be both accurate 
and precise. Small amounts of PpIX could be assayed and 
detected which is a very important feature for the screening 
of delivery systems. In addition, the method for skin reco-
very is relatively easy and rapid, and shows a high yield. 
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